Evidence map›Paper›PMID 42550995›Full record

ArticleJCO precision oncology2026

Evaluating the Prognostic Impact of IDH Mutations in Intrahepatic Cholangiocarcinoma.

Rachel N Harvey, Rebecca Gelfer, Esther Drill, Vinod Balachandran, Michael D'Angelica, Jeffrey Drebin, T Peter Kingham, Lily Saadat, Kevin Soares, Alice C Wei and 8 more

Abstract read
In one paragraph

Article in JCO precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Rachel N HarveyDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0002-0156-5236
Rebecca GelferDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0002-7270-8249
Esther DrillDepartment of Epidemiology and Biostatistics, Biostatistics Service, Memorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0002-3315-4538
Vinod BalachandranDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.
Michael D'AngelicaDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.
Jeffrey DrebinDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.
T Peter KinghamDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.ORCID 0009-0003-4595-8749
Lily SaadatDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.
Kevin SoaresDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0002-0406-017X
Alice C WeiDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0002-2505-959X
Ghassan K Abou-AlfaWeill Cornell Medical College, New York, NY.ORCID 0000-0002-1522-8054
Andrea CercekWeill Cornell Medical College, New York, NY.ORCID 0000-0002-5054-8192
James J HardingWeill Cornell Medical College, New York, NY.ORCID 0000-0002-7029-4310
Eileen M O'ReillyWeill Cornell Medical College, New York, NY.ORCID 0000-0002-8076-9199
Michail DoukasDepartment of Pathology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.ORCID 0000-0002-8611-840X
Marjolein Y V HomsDepartment of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
Bas Groot KoerkampDepartment of Surgery, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.ORCID 0000-0003-1917-6973
William R JarnaginDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0002-1635-5768

Funding

Weill Cornell/Rockefeller/Sloan-Kettering MST ProgramT32GM007739 · NIGMS · WEILL MEDICAL COLL OF CORNELL UNIV · PI HSU, KATHARINE C · 1985 to 2023
$51.1M
Characterizing Oncogenic Nras in IDH1 Mutant AML Leukemogenesis and Therapeutic ResponsivenessF30CA284575 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI Rebecca Gelfer · 2024 to 2026
$164k
NCI NIH HHS F30 CA284575NIGMS NIH HHS T32 GM007739
6 · The paper itself

Abstract

purposeIsocitrate dehydrogenase 1 and 2 (

methodsAdults from two medical centers (MSKCC and Erasmus) with ICC treated with curative-intent resection (resected) or managed nonoperatively (unresectable) who underwent next-generation sequencing were analyzed retrospectively. Kaplan-Meier and Cox regressions assessed the impact of IDH status on outcomes.

resultsOf the 795 patients analyzed, 25% had

conclusionIn this cohort of patients with ICC,

Indexed as

Bile Duct NeoplasmsCholangiocarcinomaIsocitrate DehydrogenaseMutationAgedFemaleHumansMaleMiddle AgedPrognosisRetrospective StudiesIDH1 protein, humanIDH2 protein, humanIsocitrate Dehydrogenase

Identifiers

PMID42550995
PMCPMC13662602

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.